

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 17 March 2021

Situation Report No. 248 - Kingdom of Bahrain

18<sup>th</sup> of March, 2021



World Health Organization

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	<b>120,383,919</b>	<b>2,664,386</b>	<b>6,972,925</b>	<b>151,561</b>
<b>New</b>	<b>739,668 in 2 days</b>	<b>14,190 in 2 days</b>	<b>75,654 in 2 days</b>	<b>916 in 2 days</b>


## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
<b>Total</b>	<b>133,137</b>	<b>126,080</b>	<b>489</b>	<b>6,568</b>	<b>64</b>	<b>3,352,601</b>	<b>374,873</b>	<b>222,573</b>
<b>New</b>	<b>1,454 in 2 days</b>	<b>1,257 in 2 days</b>	<b>4 in 2 days</b>	<b>-</b>	<b>-</b>	<b>31,359 in 2 days</b>	<b>-</b>	<b>-</b>


## HIGHLIGHTS

- The Mortality were: 86 years old Male Bahraini Citizens, 52 years old female Bahraini Citizens and 2 Male expatriates (40 and 65 years old).
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 17 March 2021 for the first dose (374,873) and for the second dose (222,573).
- MOH Undersecretary indicated that Bahrain is continuing with its mitigation efforts and once again stressed the importance of adhering to precautionary measures particularly given the ease of restrictions on certain activities.
- MOH Undersecretary acknowledged that COVID-19 vaccines are a pathway to normality return, highlighting successes of National Vaccination Campaign's in working with manufacturers to make vaccines available for all citizens and residents free of charge, recent success include the delivery of 300,000 doses of Sinopharm vaccines.
- MOH Undersecretary noted that the Kingdom's vaccine uptake plan is evolving, but remains focused on reaching vulnerable groups at greatest risk of developing complications from COVID-19, including those over 70 and those with underlying conditions.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue serosurveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assays; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for aCOVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guidelines: The rapids and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.
- WHO: COVID-19 Virtual Press conference transcript; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO: Weekly operational update on COVID-19 - 16 March 2021; see link below.
- WHO statement on AstraZenca COVID-19 vaccine safety signals; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d449a76\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d449a76_4)
- WHO's COVID-19 dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/press-releases/20210310-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue serosurveys: <https://www.who.int/publications/m/item/79b39-4-212258-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2v5dtr>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: <https://www.who.int/publications/m/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assays: <https://bit.ly/2v5dtr>
- WHO: Global TB progress a trisk: <https://bit.ly/2v5dtr>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2v5dtr>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS: <https://bit.ly/2v5dtr>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/2v5dtr>
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work: <https://bit.ly/2v5dtr>
- WHO: The push for a COVID-19 vaccine: <https://bit.ly/2v5dtr>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/2v5dtr>
- WHO Living Guidelines: The rapids and COVID-19: <https://www.who.int/publications/m/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/m/item/WHO-2019-nCoV-HCF\\_assessment-Products-2020.1](https://www.who.int/publications/m/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1)
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/m/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: [https://www.who.int/publications/m/item/WHO-2019-nCoV\\_health\\_workforce\\_2020.1-eng.pdf](https://www.who.int/publications/m/item/WHO-2019-nCoV_health_workforce_2020.1-eng.pdf)
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/1066533753>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: [https://www.who.int/publications/m/item/WHO-2019-nCoV\\_risk-based-international-travel-2020.1](https://www.who.int/publications/m/item/WHO-2019-nCoV_risk-based-international-travel-2020.1)
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/m/item/WHO-2019-nCoV\\_risk-assessment-international-travel-2020.1](https://www.who.int/publications/m/item/WHO-2019-nCoV_risk-assessment-international-travel-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news-room/press-releases/20210310-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/m/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/20210312-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca: <https://www.who.int/publications/m/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazenca>
- WHO: Rotavirus vaccines made available for use in humanitarian crises: <https://www.who.int/news/20210312-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises>
- WHO: COVID-19 Virtual Press conference transcript: <https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript-8-march-2021>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/20210310-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/m/item/who-guideline-development-group-living-guidelines-for-covid-19-biographies>
- WHO: Weekly operational update on COVID-19 - 16 March 2021: <https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-16-march-2021>
- WHO statement on AstraZenca COVID-19 vaccine safety signals: <https://www.who.int/news/20210321-2021-who-statement-on-astrazenca-covid-19-vaccine-safety-signals>

## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAIi@health.gov.bh](mailto:NAIi@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)